320 related articles for article (PubMed ID: 18443855)
1. Antireflux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study.
Cadière GB; Buset M; Muls V; Rajan A; Rösch T; Eckardt AJ; Weerts J; Bastens B; Costamagna G; Marchese M; Louis H; Mana F; Sermon F; Gawlicka AK; Daniel MA; Devière J
World J Surg; 2008 Aug; 32(8):1676-88. PubMed ID: 18443855
[TBL] [Abstract][Full Text] [Related]
2. Laparoscopic Hiatal Hernia Repair Followed by Transoral Incisionless Fundoplication With EsophyX Device (HH + TIF): Efficacy and Safety in Two Community Hospitals.
Janu P; Shughoury AB; Venkat K; Hurwich D; Galouzis T; Siatras J; Streeter D; Korman K; Mavrelis G; Mavrelis P
Surg Innov; 2019 Dec; 26(6):675-686. PubMed ID: 31431138
[TBL] [Abstract][Full Text] [Related]
3. Long-term benefit of transoral incisionless fundoplication using the esophyx device for the management of gastroesophageal reflux disease responsive to medical therapy.
Stefanidis G; Viazis N; Kotsikoros N; Tsoukalas N; Lala E; Theocharis L; Fassaris A; Manolakopoulos S
Dis Esophagus; 2017 Feb; 30(3):1-8. PubMed ID: 27868281
[TBL] [Abstract][Full Text] [Related]
4. Transoral incisionless fundoplication (TIF 2.0) with EsophyX for gastroesophageal reflux disease: long-term results and findings affecting outcome.
Testoni PA; Vailati C; Testoni S; Corsetti M
Surg Endosc; 2012 May; 26(5):1425-35. PubMed ID: 22170317
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of transoral incisionless fundoplication with Esophyx (Tif 2.0) and factors affecting outcomes in GERD patients followed for up to 6 years: a prospective single-center study.
Testoni PA; Testoni S; Mazzoleni G; Vailati C; Passaretti S
Surg Endosc; 2015 Sep; 29(9):2770-80. PubMed ID: 25480624
[TBL] [Abstract][Full Text] [Related]
6. Clinical and pH-metric outcomes of transoral esophagogastric fundoplication for the treatment of gastroesophageal reflux disease.
Bell RC; Freeman KD
Surg Endosc; 2011 Jun; 25(6):1975-84. PubMed ID: 21140170
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease.
Witteman BP; Conchillo JM; Rinsma NF; Betzel B; Peeters A; Koek GH; Stassen LP; Bouvy ND
Am J Gastroenterol; 2015 Apr; 110(4):531-42. PubMed ID: 25823768
[TBL] [Abstract][Full Text] [Related]
8. Three-year results of a multicenter prospective study of transoral incisionless fundoplication.
Muls V; Eckardt AJ; Marchese M; Bastens B; Buset M; Devière J; Louis H; Rajan A; Daniel MA; Costamagna G
Surg Innov; 2013 Aug; 20(4):321-30. PubMed ID: 22968006
[TBL] [Abstract][Full Text] [Related]
9. Two-year results of a feasibility study on antireflux transoral incisionless fundoplication using EsophyX.
Cadière GB; Van Sante N; Graves JE; Gawlicka AK; Rajan A
Surg Endosc; 2009 May; 23(5):957-64. PubMed ID: 19288158
[TBL] [Abstract][Full Text] [Related]
10. Endoluminal fundoplication by a transoral device for the treatment of GERD: A feasibility study.
Cadière GB; Rajan A; Germay O; Himpens J
Surg Endosc; 2008 Feb; 22(2):333-42. PubMed ID: 18071818
[TBL] [Abstract][Full Text] [Related]
11. Effect of transoral incisionless fundoplication on symptoms, PPI use, and ph-impedance refluxes of GERD patients.
Testoni PA; Corsetti M; Di Pietro S; Castellaneta AG; Vailati C; Masci E; Passaretti S
World J Surg; 2010 Apr; 34(4):750-7. PubMed ID: 20091308
[TBL] [Abstract][Full Text] [Related]
12. Transoral incisionless fundoplication effective in eliminating GERD symptoms in partial responders to proton pump inhibitor therapy at 6 months: the TEMPO Randomized Clinical Trial.
Trad KS; Barnes WE; Simoni G; Shughoury AB; Mavrelis PG; Raza M; Heise JA; Turgeon DG; Fox MA
Surg Innov; 2015 Feb; 22(1):26-40. PubMed ID: 24756976
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes after transoral incisionless fundoplication in patients with GERD and LPR symptoms.
Trad KS; Turgeon DG; Deljkich E
Surg Endosc; 2012 Mar; 26(3):650-60. PubMed ID: 21959689
[TBL] [Abstract][Full Text] [Related]
14. Transoral fundoplication offers durable symptom control for chronic GERD: 3-year report from the TEMPO randomized trial with a crossover arm.
Trad KS; Fox MA; Simoni G; Shughoury AB; Mavrelis PG; Raza M; Heise JA; Barnes WE
Surg Endosc; 2017 Jun; 31(6):2498-2508. PubMed ID: 27655380
[TBL] [Abstract][Full Text] [Related]
15. Transoral Incisionless Fundoplication TIF 2.0 with "EsophyX Z®" Device for GERD: Seven Years after Endo Lumenal Fundoplication. World’s First Case Report.
Nicolau AE; Lobonţiu A
Chirurgia (Bucur); 2018; 113(6):849-856. PubMed ID: 30596372
[TBL] [Abstract][Full Text] [Related]
16. Transoral incisionless fundoplication for recurrent symptoms after laparoscopic fundoplication.
Ghosh G; Choi AY; Dbouk M; Greenberg J; Zarnegar R; Murray M; Janu P; Thosani N; Dayyeh BKA; Diehl D; Nguyen NT; Chang KJ; Canto MI; Sharaiha R;
Surg Endosc; 2023 May; 37(5):3701-3709. PubMed ID: 36650353
[TBL] [Abstract][Full Text] [Related]
17. Randomised clinical trial: transoral incisionless fundoplication vs. sham intervention to control chronic GERD.
Håkansson B; Montgomery M; Cadiere GB; Rajan A; Bruley des Varannes S; Lerhun M; Coron E; Tack J; Bischops R; Thorell A; Arnelo U; Lundell L
Aliment Pharmacol Ther; 2015 Dec; 42(11-12):1261-70. PubMed ID: 26463242
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Laparoscopic Nissen Fundoplication vs Transoral Incisionless Fundoplication or Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease: A Systematic Review and Network Meta-analysis.
Richter JE; Kumar A; Lipka S; Miladinovic B; Velanovich V
Gastroenterology; 2018 Apr; 154(5):1298-1308.e7. PubMed ID: 29305934
[TBL] [Abstract][Full Text] [Related]
19. A prospective multicenter registry of patients with chronic gastroesophageal reflux disease receiving transoral incisionless fundoplication.
Bell RC; Mavrelis PG; Barnes WE; Dargis D; Carter BJ; Hoddinott KM; Sewell RW; Trad KS; DaCosta Gill B; Ihde GM
J Am Coll Surg; 2012 Dec; 215(6):794-809. PubMed ID: 22939637
[TBL] [Abstract][Full Text] [Related]
20. The TEMPO Trial at 5 Years: Transoral Fundoplication (TIF 2.0) Is Safe, Durable, and Cost-effective.
Trad KS; Barnes WE; Prevou ER; Simoni G; Steffen JA; Shughoury AB; Raza M; Heise JA; Fox MA; Mavrelis PG
Surg Innov; 2018 Apr; 25(2):149-157. PubMed ID: 29405886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
